High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis

Objective To determine the relationship of disease activity to infections in patients with rheumatoid arthritis (RA). Methods From the CORRONA database, the incidence of physician-reported infections in RA patients on stable disease-modifying antirheumatic drug, biological, and corticosteroid therapy for at least 6 months was ascertained. Two composite measures of disease activity were defined: clinical disease activity index (CDAI) and disease activity score 28 (DAS28). Incident rate ratios (IRR) were calculated using generalised estimating equation Poisson regression models adjusted for demographics, medications and clinical factors. Results Of 1 6242 RA patients, 6242 were on stable therapy for at least 6 months and were eligible for analysis. 2282 infections were reported in the cohort, followed over 7290 patient-years. After controlling for possible confounders, disease activity was associated with an increased rate of infections. Each 0.6 unit increase in DAS28 score corresponded to a 4% increased rate of outpatient infections (IRR 1.04, p=0.01) and a 25% increased rate of infections requiring hospitalisation (IRR 1.25, p=0.03). There was a dichotomy in the relationship between infections and CDAI scores. For CDAI <10 (mild disease activity) patients had a 12% increased rate of outpatient infections with each 5 unit increase in CDAI score (IRR 1.12, p=0.003). At CDAI scores ≥10, there was no further increase in the rate of outpatient infections associated with higher disease activity. The relationship of CDAI to hospitalised infections showed similar trends to outpatient data but did not reach statistical significance after multivariate analysis (CDAI <10: IRR 1.56, p=0.08). Conclusions In this large cohort of RA patients, higher disease activity was associated with a higher probability of developing infections.

[1]  D. Solomon,et al.  Validity of physician-reported hospitalized infections in a US arthritis registry. , 2009, Rheumatology.

[2]  W. Bishai,et al.  Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry , 2009, Annals of the rheumatic diseases.

[3]  T. Pincus,et al.  Mortality in rheumatoid arthritis: 2008 update. , 2008, Clinical and experimental rheumatology.

[4]  T. Einarson,et al.  The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events , 2008, Annals of the rheumatic diseases.

[5]  M. Abrahamowicz,et al.  Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[6]  Hyon K. Choi,et al.  The risk of hospitalized infection in patients with rheumatoid arthritis. , 2008, The Journal of rheumatology.

[7]  T. Therneau,et al.  The widening mortality gap between rheumatoid arthritis patients and the general population. , 2007, Arthritis and rheumatism.

[8]  C. Kelly,et al.  Acute lower respiratory tract infections in patients with rheumatoid arthritis. , 2007, The Journal of rheumatology.

[9]  J. Smolen,et al.  The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. , 2007, Best practice & research. Clinical rheumatology.

[10]  M. Hudson,et al.  Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. , 2007, Rheumatology.

[11]  Sebastian Schneeweiss,et al.  Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis , 2007 .

[12]  H. Paulus,et al.  Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort , 2007, Annals of the rheumatic diseases.

[13]  J. Allison,et al.  Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. , 2007, Arthritis and rheumatism.

[14]  A. Silman,et al.  Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.

[15]  Matthias Schneider,et al.  Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.

[16]  J. Kremer,et al.  The CORRONA database. , 2006, Autoimmunity reviews.

[17]  J. Smolen,et al.  The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.

[18]  H. Oiwa,et al.  Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study , 2005, Annals of the rheumatic diseases.

[19]  D. Symmons,et al.  National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. , 2003, The Journal of rheumatology.

[20]  L A Criswell,et al.  Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women’s Health Study , 2002, Annals of the rheumatic diseases.

[21]  S. Gabriel,et al.  Predictors of infection in rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[22]  S. Gabriel,et al.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.

[23]  W. Pan Akaike's Information Criterion in Generalized Estimating Equations , 2001, Biometrics.

[24]  J. Alcocer-Varela,et al.  Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. , 1998, The Journal of rheumatology.

[25]  P. van Riel,et al.  Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. , 1998, Arthritis and rheumatism.

[26]  Peter L. Brooks,et al.  Visualizing data , 1997 .

[27]  H. Kautiainen,et al.  Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. , 1995, Clinical and experimental rheumatology.

[28]  M. Laakso,et al.  Ten year mortality and causes of death in patients with rheumatoid arthritis. , 1985, British medical journal.

[29]  P. Sarzi-Puttini,et al.  Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. , 2009, Autoimmunity reviews.

[30]  Jeffrey N Katz,et al.  Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[31]  E. Arnesen,et al.  Total Mortality is Increased in Rheumatoid Arthritis. A 17-Year Prospective Study , 2001, Clinical Rheumatology.

[32]  P. Allebeck Increased mortality in rheumatoid arthritis. , 1982, Scandinavian Journal of Rheumatology.

[33]  P. Allebeck Increased Mortality in Rheumatoid Arthritis: The Use of a Medical Information System for Assessment of Death Risks , 1982 .

[34]  J. Baum Infection in rheumatoid arthritis. , 1971, Arthritis and rheumatism.